Darzalex Caution For Usage

Incompatibilities: This medicinal product must not be mixed with other medicinal products except those mentioned in Instructions for Use and Handling and Disposal as follows.
Instructions for Use and Handling and Disposal: Prepare the solution for infusion using aseptic technique as follows: Calculate the dose (mg), total volume (mL) of Daratumumab (Darzalex) solution required and the number of Daratumumab (Darzalex) vials needed based on patient weight.
Check that the Daratumumab (Darzalex) solution is colorless to yellow. Do not use if opaque particles, discoloration or other foreign particles are present.
Using aseptic technique, remove a volume of 0.9% Sodium Chloride from the infusion bag/container that is equal to the required volume of Daratumumab (Darzalex) solution.
Withdraw the necessary amount of Daratumumab (Darzalex) solution and dilute to the appropriate volume by adding to an infusion bag/container containing 0.9% Sodium Chloride (see Dosage & Administration). Infusion bags/containers must be made of polyvinylchloride (PVC), polypropylene (PP), polyethylene (PE) or polyolefin blend (PP+PE). Dilute under appropriate aseptic conditions. Discard any unused portion left in the vial.
Gently invert the bag/container to mix the solution. Do not shake or freeze.
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. The diluted solution may develop very small, translucent to white proteinaceous particles, as daratumumab is a protein.
Do not use if visibly opaque particles, discoloration or foreign particles are observed.
Since Daratumumab (Darzalex) does not contain a preservative, diluted solutions should be administered within 15 hours (including infusion time) at room temperature 15°C-25°C and in room light.
If not used immediately, the diluted solution can be stored prior to administration for up to 24 hours at refrigerated conditions 2°C-8°C and protected from light. Do not freeze. If stored in the refrigerator, allow the solution to come to room temperature before administration.
Administer the diluted solution by intravenous infusion using an infusion set fitted with a flow regulator and with an in-line, sterile, non-pyrogenic, low protein-binding polyethersulfone (PES) filter (pore size 0.22 or 0.2 micrometer). Polyurethane (PU), polybutadiene (PBD), PVC, PP or PE administration sets must be used.
Do not infuse Daratumumab (Darzalex) concomitantly in the same intravenous line with other agents.
Do not store any unused portion of the infusion solution for reuse. Any unused product or waste material should be disposed of in accordance with local requirements.